The specific binding of the platelet-activating factor (PAF) receptor antagonist WEB 2086 and the benzodiazepine flunitrazepam to rat hepatocytes.
Thieno-triazolodiazepines WEB 2086 and BN 50739 have been described as the potent PAF receptor antagonists. Binding of radiolabeled [3H]WEB 2086 has been widely employed to characterize PAF receptors in different cells. In a search for a PAF receptor in isolated rat hepatocytes, we discovered that the binding of [3H]WEB to rat hepatocytes was highly specific but had a relatively low affinity with a Kd of 113 nM and Bmax of 0.65 pmol/10(6) cells in freshly isolated cell suspension and Kd of 1.65 muM and Bmax of 2.0 pmol/plate in cultured hepatocytes. No consistent specific binding of [3H]PAF itself was found in the same cell preparations. The binding of [3H]flunitrazepam in the presence of the peripheral type of benzodiazepine receptor antagonist Ro 5-4864 was saturated and exhibited a K(i) of 3.8 nM and Bmax of 3.5 pmol/plate. The central type of benzodiazepine receptor antagonist clonazepam was competed for the [3H]flunitrazepam binding, however with a much lower affinity. Various antagonists inhibited the binding of [3H]WEB 2086 with a rank order BN 50739>>Ro 5-4864 > or = clonazepam. Interestingly, bicuculline, specific antagonist of GABA(A) recognition sites, also significantly reduced the binding of [3H]WEB 2086. The binding of [3H]flunitrazepam was inhibited with a rank potency BN 50739>>WEB 2086. Taken together, these findings suggest that the specific binding of PAF receptor antagonists WEB 2086 and BN 50739 in rat hepatocytes does not involve PAF receptors and occurs via peripheral benzodiazepine and, possibly GABA(A) receptor sites.
Svetlov
S I
SI
Department of Biochemistry, The University of Texas Health Science Center at San Antonio, 78284-7760, USA.
Barton
J M
JM
Olson
M S
MS
D000818:Animals; D014151:Anti-Anxiety Agents / Q000378:metabolism; D000927:Anticonvulsants / Q000494:pharmacology; D001381:Azepines / Q000378:metabolism* / Q000494:pharmacology; D001570:Benzodiazepinones / Q000494:pharmacology; D001640:Bicuculline / Q000494:pharmacology; D002478:Cells, Cultured; D002998:Clonazepam / Q000494:pharmacology; D003292:Convulsants / Q000494:pharmacology; D005445:Flunitrazepam / Q000378:metabolism*; D007700:Kinetics; D008099:Liver / Q000378:metabolism*; D008297:Male; D010975:Platelet Aggregation Inhibitors / Q000378:metabolism*; D010980:Platelet Membrane Glycoproteins / Q000037:antagonists & inhibitors*; D051381:Rats; D017207:Rats, Sprague-Dawley; D011956:Receptors, Cell Surface; D043562:Receptors, G-Protein-Coupled; D014230:Triazoles / Q000378:metabolism* / Q000494:pharmacology; D014316:Tritium
D014151:Anti-Anxiety Agents; D000927:Anticonvulsants; D001381:Azepines; D001570:Benzodiazepinones; D003292:Convulsants; D010975:Platelet Aggregation Inhibitors; D010980:Platelet Membrane Glycoproteins; D011956:Receptors, Cell Surface; D043562:Receptors, G-Protein-Coupled; D014230:Triazoles; C039351:platelet activating factor receptor; D014316:Tritium; C052518:WEB 2086; C064509:BN 50739; C028513:4'-chlorodiazepam; D002998:Clonazepam; D005445:Flunitrazepam; D001640:Bicuculline